957774-01-5

Upstream product

• 608119-82-0 1-(4-(benzyloxy)-2-methylphenyl)ethanone 
• 875-59-2 4'-hydroxy-2'methylacetophenone 
• 578-39-2 4-hydroxy-2-methylbenzoic acid 
• 957774-00-4 1-[4-(benzyloxy)-5-bromo-2-methylphenyl]ethanone 
• 1000369-03-8 1-[4-(benzyloxy)-3-bromo-2-methylphenyl]ethanone 

Downstream Products

• 1000369-04-9 4-(benzyloxy)-5-bromo-2-methylbenzoyl chloride 
• 1033723-27-1 [4-(benzyloxy)-5-bromo-2-methylphenyl](4-methoxyphenyl)methanol 
• 957774-50-4 (1S)-1,5-anhydro-2,3,4,6-tetra-O-benzyl-1-[2-(benzyloxy)-5-[4-[2-[[[(2-hydroxy-1,1-dimethylethyl)amino]carbonyl]amino]ethyl]benzyl]-4-methylphenyl]-D-glucitol 
• 957774-51-5 (1S)-1,5-anhydro-2,3,4,6-tetra-O-benzyl-1-[2-(benzyloxy)-5-[4-[2-[[[[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino]carbonyl]amino]ethyl]benzyl]-4-methylphenyl]-D-glucitol 
• 1033723-28-2 (4-(benzyloxy)-5-bromo-2-methylphenyl)(4-ethylphenyl)methanol 
• 1033723-45-3 1-(benzyloxy)-2-bromo-5-methyl-4-(4-methoxybenzyl)benzene 
• 1033723-46-4 1-(benzyloxy)-2-bromo-5-methyl-4-(4-methylbenzyl)benzene 
• 1033723-47-5 1-(benzyloxy)-2-bromo-4-(4-ethylbenzyl)-5-methylbenzene 

Relevant academic research and scientific papers

Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes

The design and synthesis of a novel class of low-absorbable SGLT1 inhibitors are described. To achieve low absorption in the new series, we performed an optimization study based on a strategy to increase TPSA. Fortunately, the optimization of an aglycon m

C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHODS THEREOF, AND MEDICAL APPLICATIONS THEREOF

C-aryl glucoside derivatives, preparation methods thereof, and medical applications thereof are described. Specifically, compounds represented by formula I, and, tautomers, enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts of th

1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE

A 1-phenyl 1-thio-D-glucitol compound represented by formula (I) or the like: or a pharmaceutically acceptable salt thereof or a hydrate thereof, or a pharmaceutical preparation comprising the same as an active ingredient is useful as a novel type of prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which inhibits both SGLT1 and SGLT2 activities to achieve not only suppression of glucose absorption from the digestive tract but also excretion of urinary sugars.

C-PHENYL GLYCITOL COMPOUND

Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof wherein R1 and R2 are the same or different and represent a hydrogen atom, a hydroxyl group, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, R3 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, Y is a C1-6 alkylene group, -O-(CH2)n- (n is an integer of 1 to 4) or a C2-6 alkenylene group, provided that when Z is NHC(= NH)NH2 or -NHCON(RB)RC, n is not 1, Z is -CONHRA, -NHC(=NH)NH2 or -NHCON(RB)RC, Formula (A) or Formula (B).